[go: up one dir, main page]

WO2001000183A3 - COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS - Google Patents

COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS Download PDF

Info

Publication number
WO2001000183A3
WO2001000183A3 PCT/EP2000/005410 EP0005410W WO0100183A3 WO 2001000183 A3 WO2001000183 A3 WO 2001000183A3 EP 0005410 W EP0005410 W EP 0005410W WO 0100183 A3 WO0100183 A3 WO 0100183A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
combination
hmg
coa reductase
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005410
Other languages
German (de)
French (fr)
Other versions
WO2001000183A2 (en
Inventor
Rudi Gruetzmann
Ulrich Mueller
Hilmar Bischoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to JP2001505893A priority Critical patent/JP2003503342A/en
Priority to EP00942056A priority patent/EP1196194A2/en
Priority to AU56809/00A priority patent/AU5680900A/en
Priority to CA002376881A priority patent/CA2376881A1/en
Publication of WO2001000183A2 publication Critical patent/WO2001000183A2/en
Publication of WO2001000183A3 publication Critical patent/WO2001000183A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of a combination consisting of at least one selected MTP inhibitor (constituent A) and of at least one HMG-CoA reductase inhibitor (constituent B) for fighting cardiovascular diseases. The invention also relates to medicaments containing this combination and to the production thereof.
PCT/EP2000/005410 1999-06-25 2000-06-13 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS Ceased WO2001000183A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001505893A JP2003503342A (en) 1999-06-25 2000-06-13 Combinations of MTP inhibitors and HMG-CoA reductase inhibitors and their use in medicine
EP00942056A EP1196194A2 (en) 1999-06-25 2000-06-13 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS
AU56809/00A AU5680900A (en) 1999-06-25 2000-06-13 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
CA002376881A CA2376881A1 (en) 1999-06-25 2000-06-13 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor
DE19929065.2 1999-06-25

Publications (2)

Publication Number Publication Date
WO2001000183A2 WO2001000183A2 (en) 2001-01-04
WO2001000183A3 true WO2001000183A3 (en) 2001-05-10

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005410 Ceased WO2001000183A2 (en) 1999-06-25 2000-06-13 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS

Country Status (12)

Country Link
EP (1) EP1196194A2 (en)
JP (1) JP2003503342A (en)
AR (1) AR028996A1 (en)
AU (1) AU5680900A (en)
CA (1) CA2376881A1 (en)
DE (1) DE19929065A1 (en)
DO (1) DOP2000000022A (en)
GT (1) GT200000099A (en)
PE (1) PE20010302A1 (en)
SV (1) SV2004000109A (en)
UY (1) UY26218A1 (en)
WO (1) WO2001000183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
IL161134A0 (en) * 2002-02-28 2004-08-31 Japan Tobacco Inc Ester compound and medical use thereof
JP4832897B2 (en) * 2003-08-29 2011-12-07 日本たばこ産業株式会社 Ester derivatives and their pharmaceutical uses
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (en) * 2018-08-08 2018-12-21 中山大学 A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (en) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indole and -azaindole derivatives
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19615265A1 (en) * 1996-04-18 1997-12-04 Bayer Ag New pyridazino, pyrimido, pyrazino and triazinoindoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
GT200000099A (en) 2001-12-13
AR028996A1 (en) 2003-06-04
AU5680900A (en) 2001-01-31
PE20010302A1 (en) 2001-04-12
EP1196194A2 (en) 2002-04-17
CA2376881A1 (en) 2001-01-04
DE19929065A1 (en) 2000-12-28
JP2003503342A (en) 2003-01-28
UY26218A1 (en) 2001-01-31
WO2001000183A2 (en) 2001-01-04
DOP2000000022A (en) 2008-08-15
SV2004000109A (en) 2004-05-07

Similar Documents

Publication Publication Date Title
AU6580000A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor
HUS1200031I1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors and method for the preparation of dipeptidyl peptidase IV and pharmaceutical compositions containing them
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2002360732A1 (en) Change inhibitors of dipeptidyl peptidase iv
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
WO2004000290A8 (en) Pharmaceutical composition
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
HUP9801409A2 (en) Tetrahydroisoquinolin derivative as apo b-secretion or/and mtp inhibitor, process for producing it and pharmaceutical composition containing it
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2001000183A3 (en) COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
AU2002225796A1 (en) Tablet form of gas generant
AU2000238612A1 (en) Point of sale display
AUPQ629000A0 (en) Inhibition of fungi
WO2001000184A3 (en) Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments
EP1467978A4 (en) Pancreatic lipase inhibitor compounds, their synthesis and use
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
WO2001000189A3 (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
AU2116201A (en) A therapeutic mixture of hmg-coa reductase inhibitors
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000942056

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2376881

Country of ref document: CA

Ref country code: CA

Ref document number: 2376881

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10019007

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 505893

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000942056

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000942056

Country of ref document: EP